| 标题： | 乳腺癌靶向药物皮下注射护理专家共识 |
| title： | Expert consensus on subcutaneous injection of targeted drugs for breast cancer |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 拟实施乳腺癌靶向药物皮下注射的医务人员，包括护理管理者、临床护士、医生等 |
| Guide users： | Medical staff planning to implement subcutaneous injection of targeted drugs for breast cancer, including nursing managers, clinical nurses, doctors, etc |
| 证据分级方法： | 无 |
| Evidence grading method： | No |
| 制定单位： | 中华护理学会肿瘤护理专委会 |
| Formulating unit： | Oncology Nursing Committee of Chinese Nursing Association |
| 注册时间： | 2024-02-09 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN262 |
| Registration number： | |
| 指南制订的目的： | 人类表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性乳腺癌患者的预后因靶向药物的应用获得显著改善，HER2靶向药物的皮下剂型则为HER2阳性乳腺癌患者提供了安全、高效、便捷且经济的全新治疗方式。临床实践中，乳腺癌靶向药物皮下制剂的应用也为医护人员的规范使用及管理提出了新的要求。基于此，中华护理学会肿瘤专委会就目前国内可及的曲妥珠单抗皮下剂型、帕妥珠曲妥珠单抗（曲帕双靶）皮下剂型为例，通过改良德尔菲法，征集专家建议，形成了本共识内容，涵盖了注射前准备、注射要点、注射后的观察与记录、不良反应的护理、患者教育与随访等，为乳腺癌靶向药物皮下治疗用药管理的临床实践提供参考。 |
| Purpose of the guideline： | Innovations led by targeted drug discovery, research and development have drastically improved the outcome of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Subcutaneous formulations of HER2-targeted therapies provided safe, efficient, convenient, and economic treatment modality for HER2-positive breast cancer. Meanwhile, there have been new demands on standardized use and management of subcutaneous administration to healthcare professionals. To help the clinical practice of breast cancer targeted therapy with subcutaneous injection, Chinese Nursing Association Oncology Committee established current consensus using a modified Delphi method and soliciting experts’ opinions on trastuzumab injection and fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use, which are now available in China, covering pre-administration preparation, administration practice, post-administration observing and recording, adverse effects management, patient education and follow-up. |
最新注册
